Top 5 Undervalued Midcap Stocks to Keep an Eye On
SYNOPSIS: Five mid-cap stocks are trading below industry P/E levels despite solid fundamentals and growth, indicating potential undervaluation opportunities for investors seeking value picks across telecom, pharma, power, and renewable sectors.
The Price-to-Earnings (P/E) ratio measures a company's current share price relative to its earnings per share (EPS). It is one of the most commonly used valuation metrics by investors and analysts globally, indicating how much investors are willing to pay for every Re. 1 of a company's earnings.
A higher P/E ratio may indicate that the stock is either overvalued or that investors expect strong future growth, often driven by optimism around earnings potential. In contrast, a lower P/E ratio may suggest undervaluation due to market or company-specific risks, though it can also reflect concerns about weaker future performance. Below are a few mid-cap undervalued companies that are trading below the industry P/E (Price to Earnings) Ratio:
With a market cap of Rs. 1,05,790.33 crores, the stock moved down by around 0.93 percent and closed in the red at Rs. 401.00 on BSE during Friday's trading session. In terms of financial ratios, Indus Towers has reported an RoE of 32.5 percent and ROCE of 29 percent, while a debt-to-equity ratio of 0.58. Further, the stock is currently trading at a P/E of 15.1, below to the industry average of 17.
In Q3 FY26, the company witnessed a marginal growth of nearly 8 percent YoY in revenue from operations to Rs. 8,146 crores, accompanied by a net profit decline of around 56 percent YoY to Rs. 1,776 crores. Indus Towers Limited is engaged in the business of object of, inter-alia, setting up, operating and maintaining wireless communication towers.
With a market cap of Rs. 93,579.76 crores, the stock moved down by around 1.81 percent and closed in the red at Rs. 930.00 on BSE during Friday's trading session. In terms of financial ratios, Zydus Lifesciences has reported an RoE of 21.2 percent and ROCE of 24.3 percent, while a debt-to-equity ratio of 0.38. Further, the stock is currently trading at a P/E of 18.3, below the industry average of 30.4.
In Q3 FY26, the company witnessed a growth of nearly 30 percent YoY in revenue from operations to Rs. 6,864 crores, accompanied by a marginal net profit decline of around 0.3 percent YoY to Rs. 1,023 crores.
Zydus Lifesciences Limited operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations.
With a market cap of Rs. 73,897.98 crores, the stock moved up by around 0.26 percent and closed in the green at Rs. 53.88 on BSE during Friday's trading session. In terms of financial ratios, Suzlon has reported an RoE of 41.4 percent and ROCE of 32.5 percent, with a debt-to-equity ratio of 0.05. Further, the stock is currently trading at a P/E of 23, below the industry average of 36.
In Q3 FY26, the company witnessed a growth of nearly 42 percent YoY in revenue from operations to Rs. 4,236 crores, accompanied by a net profit growth of around 15 percent YoY to Rs. 445 crores.
Suzlon Energy Limited is primarily engaged in the business of manufacturing Wind Turbine Generators (WTGs) and the sale of related components of various capacities, project execution, power evacuation, Operation and Maintenance (O&M) of Wind Turbine Generators (WTGs) and power generation business.
With a market cap of Rs. 85,567.86 crores, the stock moved down by around 2.16 percent and closed in the red at Rs. 1698.10 on BSE during Friday's trading session. In terms of financial ratios, Torrent Power has reported an RoE of 19 percent and ROCE of 16 percent, with a debt-to-equity ratio of 0.55. Further, the stock is currently trading at a P/E of 26.4, below the industry average of 31.4.
In Q3 FY26, the company witnessed a growth of nearly 4 percent YoY in revenue from operations to Rs. 6,778 crores, accompanied by a net profit growth of around 34 percent YoY to Rs. 655 crores.
Torrent Power Limited is a leading integrated power utility company in India with presence across generation, transmission and distribution of power. Its operations are spread across the states of Gujarat, Maharashtra, Uttar Pradesh and Karnataka.
With a market cap of Rs. 82,270.55 crores, the stock moved down by around 1.35 percent and closed in the red at Rs. 1416.50 on BSE during Friday's trading session. In terms of financial ratios, Aurobindo Pharma has reported an RoE of 11.1 percent and ROCE of 14.2 percent, while a debt-to-equity ratio of 0.22. Further, the stock is currently trading at a P/E of 23.3, below the industry average of 30.4.
In Q3 FY26, the company witnessed a growth of nearly 8 percent YoY in revenue from operations to Rs. 8,646 crores, accompanied by a net profit growth of around 8 percent YoY to Rs. 910 crores.
Aurobindo Pharma Limited is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
